Ascendis Pharma A/S reports results for the quarter ended in December - Earnings Summary

Ascendis Pharma A/S

16/02/2023 21:49

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €3.70​​ per share for the quarter ended in December. The mean
expectation of twelve analysts for the quarter was for a loss of
€2.56 per share.
    * Revenue rose 511% to €29.92 million from a year ago;
analysts
expected €19.84 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€3.70​.
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * Ascendis Pharma A/S shares had fallen by 8.3% this
quarter.
    * The company reported a quarterly loss of €207.42 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $161.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
16 at 09:49 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -2.56          -3.70          Missed
 Sep. 30 2022      -2.49          -3.03          Missed
 Jun. 30 2022      -2.13          -1.46          Beat
 Mar. 31 2022      -2.00          -2.21          Missed